Endocannabinoid Levels Track with Pancreatitis Stage and Pain ↗
Case-control study of 231 people found anandamide levels rose with pancreatitis severity while 2-AG dropped with pain intensity.
Browse more cannabis research, findings, methods, and limitations.
Case-control study of 231 people found anandamide levels rose with pancreatitis severity while 2-AG dropped with pain intensity.
A single 30 mg CBD dose increased amitriptyline blood levels by 13% in healthy volunteers, demonstrating drug interaction potential even at low doses.
Disrupting cannabinoid receptors in newborn mice produced a combined ADHD/Tourette-like phenotype with vocal tics, hyperactivity, and learning deficits, especially in males.
Among 13,405 wrist fracture surgery patients, those with cannabis use disorder had double the ER visit rate and higher readmission rates within 90 days.
Review found cannabis users often need higher sedation doses for endoscopy, with inhalation users facing extra airway risks like bronchospasm.
Interviews with 34 pregnant cannabis users revealed most providers never asked about use, and patients feared judgment and child welfare reporting if they disclosed.
Among 50 children with drug-resistant epilepsy treated with CBD for at least six months, 56% had meaningful seizure reduction and 16% became seizure-free.
Survey of 82,933 Minnesota students found bias-based bullying was associated with 50-68% higher regular cannabis use among youth with minoritized identities.
Mixing legal-market cannabis with alcohol reduced word recall by about one word per trial—but only for men, not women.
Brain imaging of 1,003 young adults found heavy lifetime cannabis users had significantly lower brain activation during working memory tasks.
Survey of 484 postpartum mothers found only one-third received provider counseling about marijuana, despite 60% having ever used it.
About a third of teen dual users quit both vaping and cannabis at 7 months—and quitting vaping appeared to help with quitting cannabis too.
Longitudinal study of 5,053 US adults found health professionals became the top source for cannabis information while traditional media declined sharply.
Analysis of 16 years of national data found CUD treatment rates declined while barriers like cost, awareness, and stigma grew.
Rigorous trial of 192 youth found N-acetylcysteine was no better than placebo for cannabis use disorder when not paired with contingency management.
Lab analysis of 14 hemp cigarette brands found metal levels similar to tobacco, with lower cadmium but several brands exceeding state limits for other metals.
National survey of 94,225 women found 6.8% of pregnant women used cannabis, with first-trimester rates reaching 10-14%, mostly by smoking.
National survey of 10,361 adolescents found bisexual youth had 85% higher odds of marijuana use than heterosexual peers, with disparities varying by age and sex.
Study of 1,098 veterans found cannabis use alone was not linked to suicide risk, but combining it with hazardous drinking produced the highest risk for suicidal behavior.
Study found the endocannabinoid system drives eosinophil infiltration in eosinophilic esophagitis, with CB2 receptor blocking reducing inflammation in mice.
Large database study of ~9 million pediatric patients found cannabis use disorder linked to significantly higher rates of pelvic pain, bladder symptoms, and UTIs.
Analysis of 52,679 US adolescents found COVID-19 widened substance use disparities, with multiply-victimized youth reaching 3.5x higher marijuana use odds during the pandemic.
UK Biobank data from adults aged 40-70 found lifetime cannabis use associated with larger brain volumes in key regions and better cognitive performance.
Prospective study of 16 children with severe autism found CBD-rich extract reduced internalizing behaviors after three months, with caregivers also reporting improved mental health.
Mendelian randomization study using genetic data found potential causal links between cannabis use and increased risk of Parkinson's disease and ADHD in women.
Pilot trial of 50 adults found mindfulness-based therapy (MORE) significantly reduced cannabis and cocaine cravings in people being treated for alcohol problems.
Among 3,308 matched hip replacement patients, marijuana users had higher dislocation rates but no difference in opioid use after surgery.
Study of 93 people found lifetime cannabis use lowered the endocannabinoid 2-AG in schizophrenia patients, while non-clozapine antipsychotics altered CB2 receptors.
A new brief therapy combining trauma writing with cannabis coping skills showed early promise in three young women after sexual assault—but needs rigorous testing.
Study of 1,246 women with HIV found 27% used cannabis (twice the national average), with half changing their use frequency over 18 months.
Meta-analysis of 22 trials (3,304 people) found MET-CBT significantly increased cannabis abstinence but also had higher dropout rates.
Two-year study of 961 emerging adults found negative cannabis consequences predicted later depression more than depression predicted cannabis use, especially in women.
Systematic review of 16 prospective studies found early cannabis use onset specifically predicted cannabis use disorder, not other substance problems.
Controlled trial of 21 knee OA patients found no pain benefit from combining synthetic THC with an opioid, and the combination caused more side effects.
Analysis of nearly 25,000 cannabis-related ER visits found 21.7% involved syncope (fainting), with an 8.6-fold higher prevalence compared to non-users.
Survey of 84 youth in mood disorder treatment and 66 parents found most believe cannabis and CBD effectively treat mental health conditions.
Analysis of 2,282 cannabis edibles found most contained 100+ mg THC, with widespread use of child-appealing characters, colors, and flavors.
Pilot trial of 12 women found oral cannabis capsules (100 mg CBD/5 mg THC TID) did not outperform placebo for chemotherapy-induced nerve pain.
Two pregnant women with severe cyclic vomiting were diagnosed with cannabinoid hyperemesis syndrome after the hot bathing relief pattern was identified; symptoms resolved with cannabis cessation.
A 63-year-old woman developed Takotsubo cardiomyopathy with an ejection fraction of 15-20% after cannabis use, requiring 4 weeks of intensive cardiac support to recover.
Survey of 979 cannabis users found 23% drove within 2 hours of use, with males, frequent users, and medical cannabis patients at higher risk.
A double-blind trial of 144 cancer patients found THC:CBD oil didn't improve overall symptoms vs. placebo—but pain scores did improve specifically.
Placental tissue study found cannabis use completely eliminated endocannabinoid-mediated blood vessel relaxation and greatly reduced nitric oxide signaling.
Experiment with 3,647 adolescents found warning labels on delta-8 THC products increased perceived risk and intoxication but did not reduce use susceptibility.
French poison centers recorded 304 cases of synthetic cannabinoid 5F-AKB48, mostly in teenage males vaping the drug, with 4% experiencing seizures or coma.
Analysis of 4+ million VHA patients over 18 years found cannabis legalization drove greater CUD increases among veterans with psychiatric disorders than those without.
National surveys found cannabis use disorder increased 1.4 points more among adults with psychiatric disorders between 2001 and 2013, confirming VA findings.
Comprehensive review found CHS is increasingly common with rising cannabis potency, characterized by daily use for 2+ years, and challenging to treat due to patient skepticism.
Review of 244 urine screens from chronic opioid patients found 9.8% tested positive for THC, with inconsistent provider responses to positive results.
Case-control study of 60 people found chronic cannabis users had significantly shorter telomeres than age-matched controls, suggesting accelerated biological aging.